Clinical Trial

A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants with rheumatoid arthritis (RA). The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 33 weeks excluding screening.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-11-21; most recent amendment 2026-06-19.
Status change: Not Yet Recruiting → Recruiting 2025-12-05
Trial Details
NCT Number NCT07258849
Lead Sponsor Eli Lilly and Company
Conditions Rheumatoid Arthritis (RA)
Enrollment 141 participants
Start Date 2025-12-02
Primary Completion 2028-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-23